ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$4.73
-0.09 (-1.87%)
▼
5d:
+10.26%
30d:
-2.87%
90d:
-10.92%
BUY
HIGH Confidence
Analysis Updated: Apr 6, 2026 12:00 AM ET
Earnings: May 21, 2026
Smart Money Accumulation
ABEO is down 5.4% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 5,523 OI. Call ratio: 86% View Scanner →
Strength: 6.3/10
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.99
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.72
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $4.73, which is considered fair relative to its 30-day fair value range of $4.44 to $5.03. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.1) compared to its historical average (17.8). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $4.95.
Market Sentiment: ABEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.57 (+306.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $4.95.
Market Sentiment: ABEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.57 (+306.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$4.44 -
$5.03
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 306.0% below Wall St target ($19.57)
- NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$4.44 -
$5.03
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$4.23
Resistance Level
$4.95
Current Trend
Sideways
Technical data as of
Apr 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.08
Wall Street Target
$19.57
(+306.0%)
Revenue Growth (YoY)
-100.0%
Profit Margin
1223.1%
Valuation Premium vs History
+4.1% premium
PE vs Historical
20.1 vs 17.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$5.02
(+4%)
2-Year Target
$5.22
(+8%)
3-Year Target
$5.44
(+13%)
3-Yr Target (if PE normalizes)
(PE: 20→18)
PE COMPRESSION
$4.82
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 3.68 | Current EPS (TTM): $1.21
Bull Case
$2.45
(-45%)
Analyst growth -50.0%, PE expands to 4.1
Base Case
$2.23
(-50%)
Market implied -50.0%, PE stable at 3.7
Bear Case
$3.03
(-32%)
Severe decline -20.0%, PE contracts to 3.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 06, 2026 3:18 PM ET
Data refreshes hourly during market hours. Next update: 4:18 PM
Data refreshes hourly during market hours. Next update: 4:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Crombez
SELL
16284 shares
2026-02-02
Leila Alland
SELL
18065 shares
2026-02-02
Mark Alvino
SELL
2000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 60 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 51 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 60 BUY |
